Kynmobi

The recommended starting dose of Kynmobi (Apomorphine) sublingual is a 10 mg film, allowed to dissolve under the tongue. The medication is absorbed into your body through the skin under your tongue. Depending on how well the medication works, your doctor may gradually increase your dose to a maximum of 30 mg for each "off" episode.

If a single dose of Kynmobi (Apomorphine) is not effective for a particular "off" episode, a second dose should not be taken for that episode. Do not take a repeat dose of Kynmobi (Apomorphine) sooner than 2 hours after the last dose. Most people need 2 doses a day, spread out through the day. The maximum number of doses is 5 films used per day or a total of 90 mg, whichever is less.

Before placing a film under your tongue, take a drink of water and swallow the water. This helps the film to dissolve. Remove the film from the foil pouch and place it under your tongue, as far back as you can. Close your mouth. It can take up to 3 minutes for the film to dissolve. During this time, do not chew or swallow the film, avoid talking and try not to swallow your saliva. You can tell when the film has dissolved by checking in a mirror. After the film has completely dissolved, you can swallow. You may notice some leftover dye in your mouth after the film has dissolved.

Many things can affect the dose of medication that a person needs, such as body weight, other medical conditions, and other medications. If your doctor has recommended a dose different from the ones listed here, do not change the way that you are taking the medication without consulting your doctor.

It is important to take Kynmobi (Apomorphine) exactly as prescribed by your doctor. Kynmobi (Apomorphine) is only used during "off" episodes. If you miss a dose, skip the missed dose and take it during your next "off" episode. Do not take a double dose to make up for a missed one. If you are not sure what to do after missing a dose, contact your doctor or pharmacist for advice .

Store Kynmobi (Apomorphine) in its foil pouch at room temperature, protect it from light and moisture, and keep it out of the reach of children.

Do not dispose of medications in wastewater (e.g. down the sink or in the toilet) or in household garbage. Ask your pharmacist how to dispose of medications that are no longer needed or have expired.

10 mg
Each blue-to-green, rectangular, soluble film with "10" printed in white, contains 10 mg of Kynmobi (Apomorphine). Nonmedicinal ingredients: ammonia, butyl alcohol, dehydrated alcohol, disodium EDTA dihydrate, FD&C Blue No. 1, glycerin (natural), glyceryl monostearate, hydroxyethyl cellulose, hydroxypropyl cellulose, isopropyl alcohol, maltodextrin, menthol crystals, potassium hydroxide, propylene glycol, pyridoxine hydrochloride, shellac, sodium hydroxide, sodium metabisulfite, sucralose, and titanium dioxide. Each soluble film is individually packaged in a sealed foil pouch.

15 mg
Each blue-to-green, rectangular, soluble film with "15" printed in white, contains 15 mg of Kynmobi (Apomorphine). Nonmedicinal ingredients: ammonia, butyl alcohol, dehydrated alcohol, disodium EDTA dihydrate, FD&C Blue No. 1, glycerin (natural), glyceryl monostearate, hydroxyethyl cellulose, hydroxypropyl cellulose, isopropyl alcohol, maltodextrin, menthol crystals, potassium hydroxide, propylene glycol, pyridoxine hydrochloride, shellac, sodium hydroxide, sodium metabisulfite, sucralose, and titanium dioxide. Each soluble film is individually packaged in a sealed foil pouch.

20 mg
Each blue-to-green, rectangular, soluble film with "20" printed in white, contains 20 mg of Kynmobi (Apomorphine). Nonmedicinal ingredients: ammonia, butyl alcohol, dehydrated alcohol, disodium EDTA dihydrate, FD&C Blue No. 1, glycerin (natural), glyceryl monostearate, hydroxyethyl cellulose, hydroxypropyl cellulose, isopropyl alcohol, maltodextrin, menthol crystals, potassium hydroxide, propylene glycol, pyridoxine hydrochloride, shellac, sodium hydroxide, sodium metabisulfite, sucralose, and titanium dioxide. Each soluble film is individually packaged in a sealed foil pouch.

25 mg
Each blue-to-green, rectangular, soluble film with "25" printed in white, contains 25 mg of Kynmobi (Apomorphine). Nonmedicinal ingredients: ammonia, butyl alcohol, dehydrated alcohol, disodium EDTA dihydrate, FD&C Blue No. 1, glycerin (natural), glyceryl monostearate, hydroxyethyl cellulose, hydroxypropyl cellulose, isopropyl alcohol, maltodextrin, menthol crystals, potassium hydroxide, propylene glycol, pyridoxine hydrochloride, shellac, sodium hydroxide, sodium metabisulfite, sucralose, and titanium dioxide. Each soluble film is individually packaged in a sealed foil pouch.

30 mg
Each blue-to-green, rectangular, soluble film with "30" printed in white, contains 30 mg of Kynmobi (Apomorphine). Nonmedicinal ingredients: ammonia, butyl alcohol, dehydrated alcohol, disodium EDTA dihydrate, FD&C Blue No. 1, glycerin (natural), glyceryl monostearate, hydroxyethyl cellulose, hydroxypropyl cellulose, isopropyl alcohol, maltodextrin, menthol crystals, potassium hydroxide, propylene glycol, pyridoxine hydrochloride, shellac, sodium hydroxide, sodium metabisulfite, sucralose, and titanium dioxide. Each soluble film is individually packaged in a sealed foil pouch.

Do not take Kynmobi (Apomorphine) if you:

• are allergic to Kynmobi (Apomorphine) or any ingredients of the medication
• have had a reaction to sulfites
• are taking a nausea medication from the serotonin antagonist group of medications (e.g., Ondansetron, Granisetron, Palonosetron)
• have severely decreased liver function
• have severely decreased kidney function

There may be an interaction between Kynmobi (Apomorphine) sublingual film and any of the following:

• alcohol
• Aldesleukin
• Aliskiren
• alpha agonists (e.g., Clonidine, methyldopa)
• alpha blockers (e.g., Alfuzosin, Doxazosin, Tamsulosin)
• angiotensin converting enzyme inhibitors (ACEIs; Captopril, Enalapril, Ramipril)
• angiotensin receptor blockers (ARBs; e.g., Candesartan, Irbesartan, Losartan)
• antiarrhythmics (e.g., Amiodarone, Disopyramide, Dronedarone, procainamide, quinidine)
• antimalarials (e.g., quinine, chloroquine)
• antipsychotics (e.g., Chlorpromazine, Clozapine, Haloperidol, Olanzapine, Quetiapine, Risperidone)
• Atomoxetine
• "azole" antifungals (e.g., fluconazole, ketoconazole)
• barbiturates (e.g., butalbital, Phenobarbital)
• beta-adrenergic blockers (e.g., Atenolol, Propranolol, Sotalol)
• beta-2 agonists (e.g., salmeterol, salbutamol)
• Bromocriptine
• Bupropion
• calcium channel blockers (e.g., Amlodipine, Diltiazem, Nifedipine, Verapamil)
• Capecitabine
• ciprofloxacin
• conivaptan
• diuretics (water pills; e.g., Furosemide, Hydrochlorothiazide, triamterene)
• Domperidone
• Duloxetine
• Hydroxyzine
• iron sucrose
• laxatives (e.g., sodium phosphates)
• levodopa
• macrolide antibiotics (e.g., clarithromycin, erythromycin)
• Methadone
• Metoclopramide
• Methylphenidate
• Mirtazapine
• Morphine
• Nabilone
• nitrates (e.g., Nitroglycerin, isosorbide dinitrate, isosorbide mononitrate)
• Obinutuzumab
• Paclitaxel
• Pentoxifylline
• phosphodiesterase 5 inhibitors (e.g., Sildenafil, Tadalafil, Vardenafil)
• Pramipexole
• protein kinase inhibitors (e.g., Bosutinib, Lapatinib, Sorafenib, Sunitinib)
• Rasagiline
• rilpivirine
• Romidepsin
• Riociguat
• Ropinirole
• Rotigotine
• sacubitril
• Selegiline
• Sertraline
• serotonin antagonists (anti-emetic medications; e.g., granisetron, ondansetron)
• siponimod
• Solifenacin
• Tacrolimus
• Tamoxifen
• thalidomide
• Tizanidine
• Trazodone
• tricyclic antidepressants (e.g., Amitriptyline, Desipramine, Trimipramine)
• Vorinostat

If you are taking any of these medications, speak with your doctor or pharmacist. Depending on your specific circumstances, your doctor may want you to:

• stop taking one of the medications,
• change one of the medications to another,
• change how you are taking one or both of the medications, or
• leave everything as is.

An interaction between two medications does not always mean that you must stop taking one of them. Speak to your doctor about how any drug interactions are being managed or should be managed.

Medications other than those listed above may interact with Kynmobi (Apomorphine). Tell your doctor or prescriber about all prescription, over-the-counter (non-prescription), and herbal medications you are taking. Also tell them about any supplements you take. Since caffeine, alcohol, the Nicotine from cigarettes, or street drugs can affect the action of many medications, you should let your prescriber know if you use them.

Before you begin using a medication, be sure to inform your doctor of any medical conditions or Allergies you may have, any medications you are taking, whether you are pregnant or breast-feeding, and any other significant facts about your health. These factors may affect how you should use Kynmobi (Apomorphine).

Abnormal thinking: Medications that affect dopamine can cause changes in how a person thinks. Kynmobi (Apomorphine) may cause people to become paranoid, agitated, and aggressive. It is not unusual to experience hallucinations, confusion, or disorientation. If you notice changes in your thoughts, or you become aware that a person under your care is having changes in their thoughts, contact the doctor as soon as possible.

Alcohol: Consuming alcohol can make some of the side effects of Kynmobi (Apomorphine) worse. Avoid drinking alcohol while you are using Kynmobi (Apomorphine).

Behaviour and mood changes: Kynmobi (Apomorphine) has been known to cause mood swings, changes in behaviour, and symptoms of psychosis. If you have a history of mental health concerns, discuss with your doctor how Kynmobi (Apomorphine) may affect your medical condition, how your medical condition may affect the dosing and effectiveness of Kynmobi (Apomorphine), and whether any special monitoring is needed.

You may notice compulsive behaviour, such as gambling, increased sexual activity, or inappropriate spending. If you experience symptoms of Depression such as poor concentration, changes in weight, changes in sleep, or decreased interest in activities, contact your doctor as soon as possible. If you notice compulsive behaviour or signs of depression in a family member, ensure that they see their doctor.

Drowsiness/reduced alertness: Kynmobi (Apomorphine) may affect the mental or physical abilities needed to drive or operate machinery. Avoid driving, operating machinery, or performing other potentially hazardous tasks until you have determined how you are affected by Kynmobi (Apomorphine).

Falls: People with Parkinson's disease are more likely to experience falls because the illness prevents them from moving smoothly to correct unbalanced posture. The use of Kynmobi (Apomorphine) may increase the risk of falls due to the decreased blood pressure and changes in ability to move.

After using a dose of Kynmobi (Apomorphine), remember to rise slowly from a sitting or lying position and stay near something that offers support until you have established your balance.

Heart rhythm: Kynmobi (Apomorphine) can cause changes to the normal rhythm of the heart, including an irregular heartbeat called QT prolongation. QT prolongation is a serious life-threatening condition that can cause fainting, seizures, and sudden death. If you are at risk for heart rhythm problems (e.g., people with heart failure, Angina, low potassium or magnesium levels), discuss with your doctor how Kynmobi (Apomorphine) may affect your medical condition, how your medical condition may affect the dosing and effectiveness of Kynmobi (Apomorphine), and whether any special monitoring is needed.

Kidney function: The kidneys are partially responsible for removing Kynmobi (Apomorphine) from your body. Kidney Disease or reduced kidney function may cause Kynmobi (Apomorphine) to build up in the body, causing side effects. If you have reduced kidney function or kidney disease, discuss with your doctor how Kynmobi (Apomorphine) may affect your medical condition, how your medical condition may affect the dosing and effectiveness of Kynmobi (Apomorphine), and whether any special monitoring is needed.

Liver function: Liver disease or reduced liver function may cause Kynmobi (Apomorphine) to build up in the body, causing side effects. If you have liver problems, discuss with your doctor how Kynmobi (Apomorphine) may affect your medical condition, how your medical condition may affect the dosing and effectiveness of Kynmobi (Apomorphine), and whether any special monitoring is needed. Your doctor may want to test your liver function regularly with blood tests while you are taking Kynmobi (Apomorphine).

Low blood pressure: Kynmobi (Apomorphine) can cause blood pressure to drop, particularly when rising from a sitting or lying position. The combination of decreased blood pressure and improved mobility can contribute to the risk of falls for people with Parkinson's disease. If you feel dizzy or lightheaded or feel your pulse is racing, and this feeling does not go away after a few minutes, call your doctor. Because Kynmobi (Apomorphine) can cause dizziness or lightheadedness, do not get up too quickly after you have been sitting or lying for prolonged periods. If you have heart disease (e.g., heart failure, heart attack) or are taking medications that lower blood pressure, discuss with your doctor how Kynmobi (Apomorphine) may affect your medical condition, how your medical condition may affect the dosing and effectiveness of Kynmobi (Apomorphine), and whether any special monitoring is needed.

Melanoma: People with Parkinson's disease may be at increased risk of developing melanoma (a type of skin cancer). It is not known if this increased risk is due to Parkinson's disease or to the medications used to treat Parkinson's disease. Your doctor will monitor you for skin cancer while you are taking Kynmobi (Apomorphine). Talk to your doctor if you have any concerns.

Nausea and vomiting: Kynmobi (Apomorphine) may cause nausea and vomiting when it is taken at normal doses. Your doctor will likely prescribe a medication to prevent these effects, to be started a few days before the first dose of Kynmobi (Apomorphine).

Neuroleptic malignant syndrome (NMS): Rarely, Kynmobi (Apomorphine) can cause a potentially fatal syndrome known as neuroleptic malignant syndrome (NMS). If you notice the symptoms of NMS such as high fever, muscle stiffness, confusion or loss of consciousness, sweating, racing or irregular heartbeat, or fainting, get immediate medical attention.

Stopping the medication: If Kynmobi (Apomorphine) needs to be stopped, it should be done gradually, under the supervision of your doctor. Stopping Kynmobi (Apomorphine), even when done by slowly reducing the amount of medication you take, can cause symptoms of withdrawal, which may be of concern to some people. Withdrawal symptoms may include anxiety or depression, unusual tiredness, trouble sleeping, sweating, irritability, and pain. If Kynmobi (Apomorphine) needs to be stopped, talk to your doctor.

Sudden onset of sleep: There are reports of people who take Kynmobi (Apomorphine) falling asleep with no warning or drowsiness. If you have a sleep disorder or you have experienced this with other medications to treat Parkinson's disease, discuss this with your doctor. If you experience drowsiness while taking Kynmobi (Apomorphine), avoid driving or using machinery.

Pregnancy: Kynmobi (Apomorphine) should not be used during pregnancy unless the benefits outweigh the risks. If you become pregnant while taking Kynmobi (Apomorphine), contact your doctor immediately.

Breast-feeding: It is not known if Kynmobi (Apomorphine) passes into breast milk. If you are a breast-feeding mother and are taking Kynmobi (Apomorphine), it may affect your baby. Talk to your doctor about whether you should continue breast-feeding.

Children: The safety and effectiveness of using Kynmobi (Apomorphine) have not been established for children.

Seniors: Seniors are more likely to experience severe adverse side effects when taking Kynmobi (Apomorphine). Kynmobi (Apomorphine) is more likely to be prescribed at lower doses for seniors to reduce this risk.